Table 3.
Various immunomodulation strategies based on the controlled release of biological molecules from hydrogels for the treatment of chronic wounds
Biological molecules | Type | Composition | Results | Reference |
---|---|---|---|---|
Cytokines | IL-10 | Dextrin nanogel | Slow release of IL-10 reduced TNF-α synthesis and down-regulated class II major histocompatibility complex molecules expression on macrophages | [181a] |
IL-10 | Collagen– silica hydrogel including PEI-DNA complexes | Decreased TNF-α and IL-1β gene expression confirmed successful inhibition of inflammation. | [181d] | |
IL-10 | Nanocomposite hydrogel based on plasmid DNA-PEI-SiNP, collagen | Controlled release of IL-10 resulted in downregulation of TNF-α expression | [181e] | |
IL-2 | An injectable hydrogel based on collagen, HA, and heparin | Sustained release of IL-2 in a two-week period decreased CD4+ and CD8+ T cells and increased FoxP3+ Treg in lymph nodes of mice. Increase immune tolerance in autoimmune diabetes | [249] | |
SDF-1α | liposomes | Improve the granulation tissue formation and accelerate diabetic wound healing | [250] | |
SDF-1α | liposome/GelMA | Effectively induce MSC migration. Controlled release of SDF-1α modulated intracellular cell signaling pathways in MSCs. | [251] | |
IL-4 and MCP-1 | Nanofibrous peptide hydrogel | Controlled release of IL-4 and MCP-1 led to spatiotemporal activation of THP-1 macrophages and improvement of proresolution M2 | [183] | |
Antibody | anti-TNF-α antibody | Chitosan | Slow release of anti-TNF-α antibody accelerated chronic wound treatment | [189a] |
anti-TNF-α antibody | Shear-thinned glycosyl–nucleoside–lipid amphiphiles | Release of entrapped anti-TNF-α accelerated autoimmune disease treatment | [189b] | |
anti-TNF-α antibody | HA hydrogel | Controlled release of anti-TNF-α antibody reduced inflammation in burns. | [189c] | |
Anti-inflammatory factor | Resolvin D1 | Chitosan | Release of resolvin D1 decreased M1 cells and increased in M2 cells. Decrease pro-inflammatory cytokines expression leading to less inflammatory cells in implant sites. | [191] |
Catechol | Chitosan and oxidized HA | Support hBMSCs against oxidative stress damages induced by ROS | [194] | |
GM-CSF + BDC peptide | Alginate-Au NPs hydrogel | Induce Treg response via delivering peptide antigen to dendritic cells (DCs). The hydrogel was proposed for the treatment of autoimmune diseases such as type 1 diabetes mouse model. | [108] | |
Peptides | L-12 peptides | Crosslinked polyanionic DNA nanostructure | Significant antimicrobial properties against S. aureus infections and noticeable anti-inflammatory response to accelerate the healing rates | [203] |
LL-37 peptides | Chitosan | Significant antibacterial properties. Inhibit TNF-α release from macrophage, improve the density of newly-formed capillary with naked LL-37 and promote the expression of key macromolecules in the angiogenesis process. | [204] | |
Pep4, Pep4M | HA hydrogel | No need for whole elastase inhibition in normal wound healing process | [252] | |
Gene | PDRN a | An assembling nanofiber gel | Improve the new vessel formation and treatment of diabetic foot ulcers in a mouse model. | [253] |
siRNA | LPEI hydrogel | Responsible for a high concentration of MMPs in diabetic ulcers leading to accelerated remodeling at injured site. | [212] | |
siRNA | Star-shaped hydrogel | Controlled release of siRNA reduced the expression of MMP-9 and accelerated diabetic wound healing. | [254] | |
siRNA | CD-(D3)7 a star-shaped hydrogel | Control the siRNA release from hydrogel leading to decreased expression of MMP-9 to accelerate diabetic wound healing. | [255] | |
siRNA | A pH-sensitive nanogel | Local release of siRNA induced gene knockdown | [209a] | |
miR-29b | Collagen | Regulate ECM remodeling and wound contraction in vivo | [256] | |
Cell + miRNA delivery | Supramolecular hydrogel | Control miRNA release | [257] | |
miRNA-132 | Neutral lipid emulsion mixed with pluronic F-127 gel | Improve re-epithelialization in damaged tissue | [223] | |
miR-223* | GelMA- HA nanoparticles | Improve the expression of anti-inflammatory gene Arg-1 and decrease the proinflammatory markers | [74b] | |
miR-302a and miR-155 | Light-activatable miRNA-loaded plasmonic gold nanocarriers | A sequentially release of miRNAs, using a NIR laser. Regulation of gene expression. | [258] | |
Cytokine + growth factor | TGF-β1 and IL-10 | Functionalized PEG | Control dendritic cell maturation via reduced expression of IL-12 and MHCII. | [181b] |
Cytokine +drug | IL-4, Dexamethasone | Self-assembled and injectable hydrogel | Successful anti-inflammatory macrophage polarization. Appropriate for the treatment of type 1 diabetes | [259] |
Antibody +growth factor | anti-TNF-ɑ and HGF | Self-assembling peptide/heparin hydrogel | Effectively improve the tissue repairing process | [190] |
Anti-inflammatory factor+ cytokine | FTY720+SDF-1α | Hep−N-functionalized PEG-DA hydrogel | Increase the recruitment of anti-inflammatory monocytes, improve early accumulation of the differentiated wound healing CD206+ macrophages, promote the vascularization. | [196] |
: A linear DNA sequence from human placenta, which can efficiently stimulate the adenosine A2A receptor